aspirin has been researched along with Flushing in 25 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Flushing: A transient reddening of the face that may be due to fever, certain drugs, exertion, or stress.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Novel regimens of niacin and aspirin, including orally dissolved aspirin, were effective in reducing niacin-induced flushing in a small sample of healthy adult volunteers." | 9.24 | Randomized controlled trial of different aspirin regimens for reduction of niacin-induced flushing. ( Banka, SS; Kaafarani, H; Lee, J; Levine, A; Lin, H; Thachil, R, 2017) |
| "Niacin extended-release (NER) is safe and effective for treatment of dyslipidemia." | 9.14 | Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. ( Jiang, P; Kashyap, ML; Krause, SL; Lewin, AJ; Padley, RJ; Thakkar, RB, 2009) |
| " To increase the probability of flushing, subjects received a single dose of reformulated niacin ER 2,000 mg, which is the upper limit of the approved dosage range." | 9.12 | Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. ( Cefali, EA; Kissling, CJ; McGovern, ME; Simmons, PD; Stanek, EJ, 2007) |
| "The usefulness of niceritrol as a lipid-lowering agent is limited by a prostaglandin-mediated flushing reaction after each dose occurring in the early stages of treatment." | 9.06 | Effects of aspirin upon the flushing reaction induced by niceritrol. ( Betteridge, DJ; Dickson, AC; Jay, RH, 1990) |
| "Niacin is the most effective lipid-modifying agent for raising high-density lipoprotein cholesterol levels, but it also causes cutaneous vasodilation with flushing." | 8.86 | A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. ( Jacobson, TA, 2010) |
| " The purpose of the present study was to examine 2 potential mitigation strategies for flushing and gastrointestinal (GI) events associated with DMF treatment: aspirin (ASA) 325 mg pretreatment for flushing, and slow dose titration of DMF for flushing and GI events." | 7.81 | Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate. ( Kurukulasuriya, NC; Li, J; O'Gorman, J; Phillips, G; Russell, HK; Viglietta, V, 2015) |
| "The objective of this study was to determine the incidence and severity of niacin-induced flushing and their relationship to niacin discontinuation and skipping or delaying niacin doses in clinical practice." | 7.75 | Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview. ( Ambegaonkar, BM; Kamal-Bahl, S; Watson, DJ, 2009) |
| "The relation of plasma levels of prostaglandins to the occurrence of flushing induced by niceritrol was investigated." | 7.67 | Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing. ( Kameda, K; Kihara, S; Kubo, M; Matsuzawa, Y; Nozaki, S; Tarui, S, 1987) |
| "Niacin is an effective lipid-modifying therapy whose use has been limited by suboptimal tolerability." | 6.74 | Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. ( Atiee, GJ; Dishy, V; Ebel, DL; Lai, E; Liu, F; Paolini, JF; Reilley, S; Royalty, J; Wagner, JA, 2009) |
| "Facial flushing was markedly reduced in the flushing group, but was slightly increased in the non-flushing Occidentals." | 5.27 | Aspirin attenuation of alcohol-induced flushing and intoxication in Oriental and Occidental subjects. ( Gaynor, CR; Mehl, DL; Truitt, EB, 1987) |
| " Aspirin pretreatment reduced the incidence and intensity of flushing without affecting GI events or the DR-DMF PK profile." | 5.17 | Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. ( Dawson, KT; Huang, R; Milne, GL; Nestorov, I; Novas, M; O'Gorman, J; Russell, H; Scannevin, RH; Sheikh, SI, 2013) |
| "Niacin extended-release (NER) is safe and effective for treatment of dyslipidemia." | 5.14 | Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. ( Jiang, P; Kashyap, ML; Krause, SL; Lewin, AJ; Padley, RJ; Thakkar, RB, 2009) |
| "To investigate the effect of low-dose aspirin administered in the morning or evening on the rate of discontinuation of prolonged-release nicotinic acid (Niaspan) due to flushing in patients at elevated cardiovascular risk." | 5.13 | Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk. ( Alves, JD; Darioli, R; Hostalek, U; Steinhagen-Thiessen, E; Vogt, A, 2008) |
| "The symptom scores for flushing, itching, tingling, and warmth were all significantly reduced by both aspirin regimens (p < ." | 5.08 | Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. ( Campbell, JR; Jungnickel, PW; Maloley, PA; Peddicord, TE; Vander Tuin, EL, 1997) |
| "It appears from this pilot study that preceding niacin with 325 mg of aspirin will decrease the warmth and flushing associated with niacin." | 5.07 | The effect of aspirin on niacin-induced cutaneous reactions. ( Fowler, SF; Hainer, BL; Price, SO; Whelan, AM, 1992) |
| "Niacin is the most effective lipid-modifying agent for raising high-density lipoprotein cholesterol levels, but it also causes cutaneous vasodilation with flushing." | 4.86 | A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. ( Jacobson, TA, 2010) |
| " The purpose of the present study was to examine 2 potential mitigation strategies for flushing and gastrointestinal (GI) events associated with DMF treatment: aspirin (ASA) 325 mg pretreatment for flushing, and slow dose titration of DMF for flushing and GI events." | 3.81 | Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate. ( Kurukulasuriya, NC; Li, J; O'Gorman, J; Phillips, G; Russell, HK; Viglietta, V, 2015) |
| "The objective of this study was to determine the incidence and severity of niacin-induced flushing and their relationship to niacin discontinuation and skipping or delaying niacin doses in clinical practice." | 3.75 | Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview. ( Ambegaonkar, BM; Kamal-Bahl, S; Watson, DJ, 2009) |
| "The relation of plasma levels of prostaglandins to the occurrence of flushing induced by niceritrol was investigated." | 3.67 | Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing. ( Kameda, K; Kihara, S; Kubo, M; Matsuzawa, Y; Nozaki, S; Tarui, S, 1987) |
| "Niacin is an effective lipid-modifying therapy whose use has been limited by suboptimal tolerability." | 2.74 | Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. ( Atiee, GJ; Dishy, V; Ebel, DL; Lai, E; Liu, F; Paolini, JF; Reilley, S; Royalty, J; Wagner, JA, 2009) |
| "Facial flushing was markedly reduced in the flushing group, but was slightly increased in the non-flushing Occidentals." | 1.27 | Aspirin attenuation of alcohol-induced flushing and intoxication in Oriental and Occidental subjects. ( Gaynor, CR; Mehl, DL; Truitt, EB, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banka, SS | 1 |
| Thachil, R | 1 |
| Levine, A | 1 |
| Lin, H | 1 |
| Kaafarani, H | 1 |
| Lee, J | 1 |
| Sheikh, SI | 1 |
| Nestorov, I | 1 |
| Russell, H | 1 |
| O'Gorman, J | 2 |
| Huang, R | 1 |
| Milne, GL | 1 |
| Scannevin, RH | 1 |
| Novas, M | 1 |
| Dawson, KT | 1 |
| Drexler, I | 1 |
| Traenka, C | 1 |
| von Hessling, A | 1 |
| Gensicke, H | 1 |
| Rowe, E | 1 |
| Russell, HK | 1 |
| Li, J | 1 |
| Phillips, G | 1 |
| Kurukulasuriya, NC | 1 |
| Viglietta, V | 1 |
| Alves, JD | 1 |
| Steinhagen-Thiessen, E | 1 |
| Darioli, R | 1 |
| Hostalek, U | 1 |
| Vogt, A | 1 |
| Kamal-Bahl, S | 1 |
| Watson, DJ | 1 |
| Ambegaonkar, BM | 1 |
| Dishy, V | 1 |
| Liu, F | 1 |
| Ebel, DL | 1 |
| Atiee, GJ | 1 |
| Royalty, J | 1 |
| Reilley, S | 1 |
| Paolini, JF | 1 |
| Wagner, JA | 1 |
| Lai, E | 2 |
| Thakkar, RB | 1 |
| Kashyap, ML | 2 |
| Lewin, AJ | 1 |
| Krause, SL | 1 |
| Jiang, P | 1 |
| Padley, RJ | 1 |
| Jacobson, TA | 1 |
| Langley, G | 1 |
| Smith, W | 1 |
| Nick, A | 1 |
| Rhodes, H | 1 |
| HAINING, CG | 1 |
| Cheng, K | 1 |
| Wu, TJ | 1 |
| Wu, KK | 1 |
| Sturino, C | 1 |
| Metters, K | 1 |
| Gottesdiener, K | 1 |
| Wright, SD | 1 |
| Wang, Z | 1 |
| O'Neill, G | 1 |
| Waters, MG | 1 |
| Oberwittler, H | 1 |
| Baccara-Dinet, M | 1 |
| Meyers, CD | 1 |
| Liu, P | 1 |
| Kamanna, VS | 1 |
| Cefali, EA | 1 |
| Simmons, PD | 1 |
| Stanek, EJ | 1 |
| McGovern, ME | 1 |
| Kissling, CJ | 1 |
| Papaliodis, D | 1 |
| Boucher, W | 1 |
| Kempuraj, D | 1 |
| Theoharides, TC | 1 |
| Brommer, EJ | 1 |
| Derkx, FH | 1 |
| Barrett-Bergshoeff, MM | 1 |
| Schalekamp, MA | 1 |
| Jungnickel, PW | 1 |
| Maloley, PA | 1 |
| Vander Tuin, EL | 1 |
| Peddicord, TE | 1 |
| Campbell, JR | 1 |
| Worobec, AS | 1 |
| Hoffer, A | 1 |
| Whelan, AM | 1 |
| Price, SO | 1 |
| Fowler, SF | 1 |
| Hainer, BL | 1 |
| Jay, RH | 1 |
| Dickson, AC | 1 |
| Betteridge, DJ | 1 |
| Truitt, EB | 1 |
| Gaynor, CR | 1 |
| Mehl, DL | 1 |
| Nozaki, S | 1 |
| Kihara, S | 1 |
| Kubo, M | 1 |
| Kameda, K | 1 |
| Matsuzawa, Y | 1 |
| Tarui, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of BG00012 Administered With and Without 325 mg Aspirin in Healthy Adult Volunteers[NCT01281111] | Phase 1 | 56 participants (Actual) | Interventional | 2011-02-01 | Completed | ||
| A Randomized, Double-Blind, Phase 3b Study to Evaluate Effects of Aspirin or Dose Titration on Flushing and Gastrointestinal Events Following Oral Administration of BG00012 Dosed at 240 mg BID[NCT01568112] | Phase 3 | 173 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Multicenter, Randomized, Double-Blind, Parallel, Acetylsalicylic Acid (ASA) Run-In Study to Evaluate the EFFECTS of Acetylsalicylic Acid on Niaspan®-Induced Flushing in Subjects With Dyslipidemia[NCT00626392] | Phase 3 | 277 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 98.4 |
| BG00012 | 63.2 |
| BG00012 + ASA | 69.8 |
| BG00012 Slow Titration | 68.9 |
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes. (NCT01568112)
Timeframe: Week 1 to Week 4
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 117.6 |
| BG00012 | 67.6 |
| BG00012 + ASA | 89.8 |
| BG00012 Slow Titration | 69.2 |
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 113.2 |
| BG00012 | 55.7 |
| BG00012 + ASA | 73.2 |
| BG00012 Slow Titration | 56.0 |
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of >=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 73 |
| BG00012 | 81 |
| BG00012 + ASA | 81 |
| BG00012 Slow Titration | 86 |
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 59 |
| BG00012 | 70 |
| BG00012 + ASA | 79 |
| BG00012 Slow Titration | 79 |
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration. (NCT01568112)
Timeframe: Week 1 to Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 57 |
| BG00012 | 65 |
| BG00012 + ASA | 67 |
| BG00012 Slow Titration | 71 |
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of >=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence. (NCT01568112)
Timeframe: Day 1 to Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 66 |
| BG00012 | 81 |
| BG00012 + ASA | 79 |
| BG00012 Slow Titration | 79 |
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 34 |
| BG00012 | 59 |
| BG00012 + ASA | 50 |
| BG00012 Slow Titration | 58 |
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of >=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 41 |
| BG00012 | 59 |
| BG00012 + ASA | 53 |
| BG00012 Slow Titration | 61 |
Participant-reported flushing events during the overall treatment period, recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1. (NCT01568112)
Timeframe: Day 2 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 43 |
| BG00012 | 86 |
| BG00012 + ASA | 74 |
| BG00012 Slow Titration | 93 |
Participant-reported flushing events during Weeks 1 to 4 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1. (NCT01568112)
Timeframe: Day 2 to Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 41 |
| BG00012 | 84 |
| BG00012 + ASA | 62 |
| BG00012 Slow Titration | 90 |
Participant-reported flushing events during Weeks 5 to 8 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to last 24 hours flushing score. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 24 |
| BG00012 | 86 |
| BG00012 + ASA | 67 |
| BG00012 Slow Titration | 85 |
Number of participants with clinical laboratory shifts from baseline in blood chemistry values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. ALP=alkaline phosphatase, ALT=alanine aminotransferase, AST=aspartate aminotransferase, GGT=gamma-glutamyl transferase, LDH=lactate dehydrogenase, BUN=blood urea nitrogen. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALP: shift to high; n=44, 42, 43, 42 | ALT: shift to high; n=44, 42, 43, 42 | AST: shift to high; n=44, 43, 43, 41 | GGT: shift to high; n=44, 41, 43, 42 | LDH: shift to low; n=44, 43, 43, 42 | LDH: shift to high; n=44, 43, 43, 42 | Total bilirubin: shift to high; n=44, 42, 42, 40 | BUN: shift to low; n=44, 43, 43, 42 | BUN: shift to high; n=44, 43, 41, 42 | Creatinine: shift to low; n=44, 43, 43, 42 | Creatinine: shift to high; n=44, 43, 43, 42 | Uric Acid: shift to low; n=44, 43, 43, 42 | Uric Acid: shift to high; n=44, 43, 43, 42 | Sodium: shift to low; n=44, 43, 43, 42 | Sodium: shift to high; n=44, 43, 43, 42 | Potassium: shift to low: n=44, 43, 43, 42 | Potassium: shift to high: n=44, 42, 42, 41 | Chloride: shift to low; n=44, 43, 43, 42 | Chloride: shift to high; n=44, 43, 43, 42 | Bicarbonate: shift to low; n=44, 43, 43, 42 | Bicarbonate: shift to high; n=44, 43, 43, 42 | Calcium: shift to low; n=44, 42, 43, 42 | Calcium: shift to high; n=44, 43, 43, 42 | Glucose: shift to low; n=43, 43, 41, 41 | Glucose: shift to high; n=44, 43, 43, 42 | Magnesium: shift to low; n=44, 43, 43, 42 | Magnesium: shift to high; n=44, 43, 43, 42 | Phosphorus: shift to low; n=44, 43, 43, 41 | Phosphorus: shift to high; n=44, 43, 43, 42 | Albumin: shift to low; n=44, 43, 43, 42 | Albumin: shift to high; n=44, 43, 43, 42 | Direct bilirubin: shift to high; n=44, 43, 43, 40 | Total protein: shift to low; n=44, 41, 43, 41 | Total protein: shift to high; n=44, 43, 43, 42 | |
| BG00012 | 0 | 2 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| BG00012 + ASA | 0 | 5 | 4 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| BG00012 Slow Titration | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Placebo | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with clinical laboratory shifts from baseline in hematology values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. abs=absolute (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White blood cells: shift to low; n=43, 43, 43, 41 | White blood cells: shift to high; n=44, 43, 43, 42 | Neutrophils abs: shift to low; n=42, 42, 42, 41 | Neutrophils abs: shift to high; n=44, 43, 43, 42 | Lymphocytes abs: shift to low; n=43, 43, 43, 41 | Lymphocytes abs: shift to high; n=44, 43, 42, 42 | Monocytes abs: shift to low; n=44, 43, 43, 42 | Monocytes abs: shift to high; n=44, 43, 43, 42 | Eosinophils abs: shift to low; n=44, 43, 43, 42 | Eosinophils abs: shift to high; n=44, 43, 43, 42 | Basophils abs: shift to high; n=44, 43, 43, 42 | Red blood cells: shift to low; n=44, 43, 43, 40 | Red blood cells: shift to high; n=44, 43, 43, 42 | Hemoglobin: shift to low; n=43, 41, 43, 42 | Hemoglobin: shift to high; n=44, 43, 43, 42 | Hematocrit: shift to low; n=44, 43, 43, 42 | Hematocrit: shift to high; n=43, 43, 43, 42 | Platelets: shift to low; n=44, 43, 43, 42 | Platelets: shift to high; n=44, 41, 43, 42 | |
| BG00012 | 2 | 0 | 6 | 0 | 5 | 0 | 0 | 0 | 0 | 5 | 1 | 2 | 0 | 3 | 0 | 2 | 0 | 0 | 0 |
| BG00012 + ASA | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 6 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| BG00012 Slow Titration | 0 | 0 | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Placebo | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Number of participants with clinical laboratory shifts from baseline in urinalysis values.Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. Shift to positive includes negative to positive and unknown to positive. RBC=red blood cells, WBC=white blood cells. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Specific gravity: shift to low; n=44, 43, 43, 42 | Specific gravity: shift to high; n=44, 42, 43, 42 | pH: shift to low; n=44, 43, 43, 42 | pH: shift to high; n=44, 43, 43, 42 | Blood: shift to positive; n=42, 39, 39, 42 | Color: shift to positive; n=41, 43, 41, 39 | Glucose: shift to positive; n=44, 43, 43, 41 | Ketones: shift to positive; n=44, 43, 43, 42 | Protein: shift to positive; n=44, 41, 43, 41 | Microscopic RBC; n=44, 40, 40, 41 | Microscopic WBC; n=43, 40, 41, 42 | |
| BG00012 | 0 | 0 | 0 | 0 | 6 | 1 | 2 | 7 | 1 | 4 | 9 |
| BG00012 + ASA | 0 | 2 | 0 | 0 | 1 | 4 | 1 | 9 | 1 | 1 | 3 |
| BG00012 Slow Titration | 0 | 0 | 0 | 0 | 2 | 5 | 0 | 6 | 1 | 2 | 3 |
| Placebo | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 1 | 0 | 3 | 4 |
Duration is calculated as follows: [(GI side effect) end date/time - (GI side effect) start date/time]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | hours (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nausea; n=12, 21, 21, 22 | Diarrhea; n=20, 20 17, 15 | Upper abdominal pain; n=17, 14, 19, 19 | Lower abdominal pain; n=12, 19, 17, 16 | Vomiting; n=3, 3, 3, 2 | Indigestion; n=12, 13, 12, 12 | Constipation; n=6, 8, 13, 11 | Bloating; n=14, 14, 21, 12 | Flatulence; n=23, 20, 22, 20 | |
| BG00012 | 7.05 | 2.92 | 6.67 | 13.93 | 10.08 | 16.49 | 28.20 | 16.91 | 9.06 |
| BG00012 + ASA | 10.01 | 14.66 | 15.88 | 10.84 | 1.88 | 3.80 | 14.26 | 9.68 | 68.93 |
| BG00012 Slow Titration | 2.98 | 4.97 | 3.83 | 7.75 | 0.75 | 4.91 | 20.90 | 77.24 | 63.84 |
| Placebo | 9.74 | 5.57 | 19.08 | 6.65 | 5.87 | 4.76 | 20.49 | 9.50 | 16.41 |
Duration is calculated as follows: [(GI side effect) end date/time - (GI side effect) start date/time]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects. (NCT01568112)
Timeframe: Week 1 to Week 4
| Intervention | hours (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nausea; n=10, 18, 18, 20 | Diarrhea; n=13, 20, 14, 14 | Upper abdominal pain; n=14, 14, 17, 15 | Lower abdominal pain; n=9, 18, 14, 13 | Vomiting; n=2, 2, 2, 2 | Indigestion; n=11, 11, 9, 11 | Constipation; n=4, 8, 11, 11 | Bloating; n=9, 14, 19, 11 | Flatulence; n=21, 17, 22, 19 | |
| BG00012 | 7.23 | 2.53 | 6.81 | 14.20 | 5.63 | 29.00 | 27.61 | 13.81 | 9.34 |
| BG00012 + ASA | 11.18 | 16.04 | 17.65 | 12.51 | 2.53 | 3.93 | 15.12 | 11.07 | 35.86 |
| BG00012 Slow Titration | 2.86 | 4.97 | 4.31 | 6.30 | 0.75 | 5.05 | 21.28 | 95.69 | 61.13 |
| Placebo | 10.47 | 5.20 | 21.37 | 5.40 | 4.31 | 5.08 | 17.05 | 6.70 | 12.83 |
Duration is calculated as follows: [(GI side effect) end date/time - (GI side effect) start date/time]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | hours (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nausea; n=4, 9, 6, 9 | Diarrhea; n=12, 13, 6, 8 | Upper abdominal pain; n=6, 5, 5, 5 | Lower abdominal pain; n=7, 5, 5, 9 | Vomiting; n=1, 1, 1, 0 | Indigestion; n=6, 7, 7, 5 | Constipation; n=5, 2, 4, 4 | Bloating; n=7, 8, 7, 8 | Flatulence; n=9, 13, 7, 10 | |
| BG00012 | 4.34 | 6.62 | 1.12 | 3.98 | 19.00 | 2.57 | 15.47 | 18.52 | 7.21 |
| BG00012 + ASA | 2.66 | 7.05 | 1.86 | 2.84 | 0.58 | 5.02 | 21.30 | 4.16 | 105.86 |
| BG00012 Slow Titration | 2.34 | 2.14 | 1.73 | 22.54 | NA | 1.63 | 18.24 | 85.64 | 18.48 |
| Placebo | 3.96 | 4.50 | 5.29 | 6.63 | 9.00 | 2.43 | 23.35 | 12.49 | 44.67 |
↑=increase; ↓=decrease; BL=baseline; bpm=beats per minute; SBP=systolic blood pressure; DBP=diastolic blood pressure; b/m=breaths per minute (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Temperature >38°C + ↑ from BL of ≥1°C | Pulse >120 bpm or ↑ from BL of >20 bpm | Pulse <50 bpm or ↓ from BL of >20 bpm | SBP >180 mm Hg or ↑ from BL of >40 mm Hg | SBP <90 mm Hg or ↓ from BL of >30 mm Hg | DBP >105 mm Hg or ↑ from BL of >30 mm Hg | DBP <50 mm Hg or ↓ from BL of >20 mm Hg | Respiration rate >25 b/m or ↑ from BL of ≥50% | Respiration rate 10 b/m or ↓ from BL of ≥50% | |
| BG00012 | 0 | 10 | 4 | 0 | 2 | 0 | 3 | 2 | 0 |
| BG00012 + ASA | 0 | 20 | 3 | 0 | 1 | 0 | 0 | 3 | 0 |
| BG00012 Slow Titration | 0 | 17 | 4 | 0 | 1 | 0 | 1 | 3 | 0 |
| Placebo | 0 | 8 | 11 | 1 | 1 | 0 | 1 | 1 | 0 |
Shift to 'abnormal, not adverse event' includes unknown or normal to 'abnormal, not adverse event.' Shift to 'abnormal, adverse event' includes unknown or normal to 'abnormal, adverse event.' (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | participants (Number) | |
|---|---|---|
| Shift to abnormal, not adverse event | Shift to abnormal, adverse event | |
| BG00012 | 3 | 0 |
| BG00012 + ASA | 2 | 0 |
| BG00012 Slow Titration | 4 | 0 |
| Placebo | 2 | 0 |
AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the subject at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the subject or may require intervention to prevent one of the other outcomes. An AE was considered treatment-emergent if it occurred after the start of study treatment or was present prior to the start of study treatment but subsequently worsened. (NCT01568112)
Timeframe: Day 1 up to end of Safety Follow-up (9 weeks)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Any event | Moderate or severe event | Severe event | Related event | Serious event | Discontinuation of treatment due to an event | Withdrawal from study due to an event | |
| BG00012 | 24 | 13 | 4 | 17 | 1 | 4 | 4 |
| BG00012 + ASA | 26 | 12 | 4 | 16 | 0 | 6 | 6 |
| BG00012 Slow Titration | 26 | 11 | 1 | 18 | 0 | 3 | 3 |
| Placebo | 24 | 10 | 0 | 8 | 0 | 2 | 2 |
Participant-reported flushing side effect events during the treatment period recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Overall flushing events | Overall redness events | Overall warmth events | Overall tingling events | Overall itching events | |
| BG00012 | 91 | 86 | 93 | 88 | 86 |
| BG00012 + ASA | 81 | 77 | 84 | 67 | 72 |
| BG00012 Slow Titration | 98 | 90 | 98 | 86 | 98 |
| Placebo | 41 | 27 | 41 | 23 | 20 |
Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). (NCT01568112)
Timeframe: Week 1 to Week 4
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Overall flushing events | Overall redness events | Overall warmth events | Overall tingling events | Overall itching events | |
| BG00012 | 86 | 81 | 88 | 84 | 77 |
| BG00012 + ASA | 72 | 63 | 67 | 51 | 56 |
| BG00012 Slow Titration | 98 | 88 | 95 | 83 | 95 |
| Placebo | 41 | 25 | 41 | 23 | 16 |
Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Overall flushing events | Overall redness events | Overall warmth events | Overall tingling events | Overall itching events | |
| BG00012 | 86 | 78 | 86 | 81 | 78 |
| BG00012 + ASA | 72 | 64 | 75 | 64 | 58 |
| BG00012 Slow Titration | 85 | 79 | 82 | 70 | 61 |
| Placebo | 24 | 15 | 17 | 15 | 22 |
Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. (NCT01568112)
Timeframe: Day 1 to Week 4
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nausea | Diarrhea | Upper abdominal pain | Lower abdominal pain | Vomiting | Indigestion | Constipation | Bloating | Flatulence | |
| BG00012 | 1.6 | 1.8 | 1.1 | 1.4 | 0.3 | 0.9 | 0.9 | 1.1 | 1.3 |
| BG00012 + ASA | 1.6 | 1.5 | 1.7 | 1.3 | 0.3 | 0.6 | 0.6 | 1.3 | 1.4 |
| BG00012 Slow Titration | 1.5 | 1.0 | 1.4 | 1.2 | 0.2 | 0.9 | 0.9 | 1.0 | 1.6 |
| Placebo | 0.7 | 1.0 | 0.8 | 0.5 | 0.2 | 0.7 | 0.4 | 0.5 | 1.3 |
Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nausea | Diarrhea | Upper abdominal pain | Lower abdominal pain | Vomiting | Indigestion | Constipation | Bloating | Flatulence | |
| BG00012 | 0.9 | 1.4 | 0.5 | 0.4 | 0.1 | 0.5 | 0.1 | 0.7 | 1.2 |
| BG00012 + ASA | 0.8 | 0.8 | 0.4 | 0.5 | 0.1 | 0.5 | 0.6 | 0.7 | 0.4 |
| BG00012 Slow Titration | 0.9 | 0.7 | 0.6 | 0.9 | 0.0 | 0.4 | 0.3 | 0.8 | 0.9 |
| Placebo | 0.4 | 1.0 | 0.6 | 0.6 | 0.2 | 0.4 | 0.4 | 0.5 | 0.8 |
Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). (NCT01568112)
Timeframe: Day 1 to Week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Overall flushing | Redness | Warmth | Tingling | Itching | |
| BG00012 | 4.4 | 3.8 | 4.0 | 3.4 | 3.2 |
| BG00012 + ASA | 2.4 | 1.6 | 2.3 | 1.6 | 1.3 |
| BG00012 Slow Titration | 5.6 | 5.1 | 5.2 | 4.0 | 4.3 |
| Placebo | 1.2 | 0.7 | 1.2 | 0.5 | 0.5 |
Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin.This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Overall flushing | Redness | Warmth | Tingling | Itching | |
| BG00012 | 3.8 | 3.6 | 3.9 | 3.3 | 3.1 |
| BG00012 + ASA | 3.3 | 2.9 | 3.1 | 2.3 | 2.3 |
| BG00012 Slow Titration | 3.1 | 2.9 | 2.9 | 2.2 | 1.8 |
| Placebo | 0.9 | 0.4 | 0.8 | 0.3 | 0.7 |
Flushing was assessed daily using the Flushing Assessment Tool via an e-diary and the mean number of flushing events per subject per week considered moderate or greater in severity was calculated. Flushing events were rated by the subject using a categorical scale of mild, moderate, severe, or very severe. (NCT00626392)
Timeframe: 4 weeks
| Intervention | Number of Events per Subject per Week (Mean) |
|---|---|
| Any Acetylsalicylic Acid | 0.3 |
| No Acetylsalicylic Acid | 0.8 |
Subjects assessed the severity of flushing events on a 10-point numeric rating scale of 1-3 (mild), 4-6 (moderate), 7-9 (severe), and 10 (very severe) using the Flushing Assessment Tool via an e-diary. For subjects who did not experience flushing, a score of 0 was assigned. Flushing was assessed daily. (NCT00626392)
Timeframe: 4 weeks
| Intervention | Scores on a Scale (Mean) |
|---|---|
| Any Acetylsalicylic Acid | 3.1 |
| No Acetylsalicylic Acid | 5.1 |
The maximum severity of flushing events subjects experienced during Week 1 of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated. (NCT00626392)
Timeframe: From Baseline to end of Week 1
| Intervention | Percentage of Subjects (Number) | |||||
|---|---|---|---|---|---|---|
| None | Mild | None/mild | Moderate | Severe | Very severe | |
| Any Acetylsalicylic Acid | 57 | 28 | 85 | 11 | 4 | 1 |
| No Acetylsalicylic Acid | 48 | 24 | 71 | 17 | 8 | 4 |
The maximum severity of flushing events subjects experienced during 4 weeks of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated. (NCT00626392)
Timeframe: 4 weeks
| Intervention | Percentage of Subjects (Number) | |||||
|---|---|---|---|---|---|---|
| None | Mild | None/Mild | Moderate | Severe | Very severe | |
| Any Acetylsalicylic Acid | 30 | 28 | 58 | 28 | 11 | 4 |
| No Acetylsalicylic Acid | 15 | 14 | 30 | 35 | 23 | 13 |
3 reviews available for aspirin and Flushing
| Article | Year |
|---|---|
A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
Topics: Aspirin; Attitude to Health; Coronary Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2010 |
Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment.
Topics: Aspirin; Dose-Response Relationship, Drug; Dyslipidemias; Flushing; Humans; Hypolipidemic Agents; Ni | 2006 |
Treatment of systemic mast cell disorders.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Antineoplastic Agents; Aspirin; Cholinergic An | 2000 |
9 trials available for aspirin and Flushing
| Article | Year |
|---|---|
Randomized controlled trial of different aspirin regimens for reduction of niacin-induced flushing.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Over Studies; Dose-Response Relations | 2017 |
Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Dela | 2013 |
Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Dela | 2008 |
Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Topics: Administration, Oral; Adult; Aged; Aspirin; Cross-Over Studies; Cyclooxygenase Inhibitors; Delayed-A | 2009 |
Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
Topics: Administration, Oral; Adult; Aged; Aspirin; Delayed-Action Preparations; Dose-Response Relationship, | 2009 |
Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Over Studies; Delayed- | 2007 |
Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions.
Topics: Adult; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Over Stud | 1997 |
The effect of aspirin on niacin-induced cutaneous reactions.
Topics: Adult; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Flushing; Humans; Hyperlipid | 1992 |
Effects of aspirin upon the flushing reaction induced by niceritrol.
Topics: Adolescent; Adult; Aspirin; Flushing; Humans; Male; Middle Aged; Niceritrol; Nicotinic Acids; Random | 1990 |
13 other studies available for aspirin and Flushing
| Article | Year |
|---|---|
Internal carotid artery dissection and asymmetrical facial flushing: the Harlequin sign.
Topics: Aspirin; Autonomic Nervous System Diseases; Carotid Artery, Internal, Dissection; Female; Flushing; | 2014 |
[Psoriasis therapy. Dose regulation or aspirin to control flush].
Topics: Aspirin; Flushing; Fumarates; Germany; Guideline Adherence; Humans; Psoriasis | 2014 |
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
Topics: Abdominal Pain; Adult; Aspirin; Constipation; Delayed-Action Preparations; Diarrhea; Dimethyl Fumara | 2015 |
Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Data Collection; Female; Flushing; Hu | 2009 |
Tramadol-induced flushing managed with aspirin premedication.
Topics: Analgesics, Opioid; Antipyretics; Aspirin; Female; Flushing; Humans; Premedication; Tramadol | 2010 |
EFFECTS OF ANTI-RHEUMATIC COMPOUNDS AND PYRIDINE DERIVATIVES ON THE CUTANEOUS RESPONSE TO THURFYL NICOTINATE IN THE GUINEA-PIG.
Topics: Animals; Antirheumatic Agents; Aspirin; Flushing; Furans; Guinea Pigs; Niacin; Nicotinic Acids; Phar | 1963 |
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.
Topics: Adolescent; Adult; Animals; Aspirin; Female; Flushing; Humans; Hydantoins; Male; Mice; Mice, Inbred | 2006 |
Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush.
Topics: Aspirin; Calcimycin; Calcium; Flushing; Humans; Macrophages; Models, Biological; Niacin; Nicotinic A | 2007 |
The flavonoid luteolin inhibits niacin-induced flush.
Topics: Animals; Aspirin; Body Temperature; Disease Models, Animal; Flushing; Hypolipidemic Agents; Luteolin | 2008 |
The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIII-antigen to infusion of DDAVP.
Topics: Antigens; Arginine Vasopressin; Aspirin; Blood Pressure; Deamino Arginine Vasopressin; Factor VIII; | 1984 |
Niacin reaction.
Topics: Aspirin; Flushing; Humans; Niacin | 1992 |
Aspirin attenuation of alcohol-induced flushing and intoxication in Oriental and Occidental subjects.
Topics: Alcoholic Intoxication; Asian People; Aspirin; Blood Pressure; Ethanol; Flushing; Heart Rate; Humans | 1987 |
Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aspirin; Cholesterol; Dinoprostone; Flushing; Humans; Hyp | 1987 |